Aravive Investor Presentation Deck

P1b ccRCC Study: Safety Profile Consistent with the Established Safety Profile for Cabozantinib Safety Batiraxcept-Related Deaths Grade 3 Adverse Events (AES), related to Batiraxcept (No Grade 4 or 5 AEs related to Batiraxcept)¹ AEs Leading to Batiraxcept Treatment Discontinuation AES of Special Interest (Infusion Related Reaction) All P1b Patients (N= 26) 5 (19.2%) Events: HTN (x2), Thrombocytopenia, Embolism, SBO, diarrhea 3 (11.5%) Events: Decreased appetite, IRR, Fatigue, Diarrhea, Gl hemorrhage 3 7 (26.9%) 15 mg/kg P1b Patients (N=16) 3 (18.8%) Events: HTN (x2), Thrombocytopenia 1 (6.3%) ² Events: Decreased appetite, Diarrhea, Fatigue 4 (25%) 20 mg/kg P1b Patients (N=10) 2 (20%) Events: Diarrhoea, Embolism, SBO 2 (20%) Events: IRR, Fatigue, Diarrhea, GI hemorrhage 3 3 (30%) ¹ HTN, thrombocytopenia, small bowel obstruction (SBO), and diarrhea were transient and resolved while batiraxcept therapy continued. Patient's cabozantinib interrupted during embolism but batiraxcept dosing continued. All events have been reported with cabozantinib use. Patient discontinued batiraxcept due to grade 2 diarrhea combined with the lack of care giver support. 3 GI hemorrhage was deemed not related to batiraxcept and possibly related to cabozantinib and led to death. Data cutoff August 8, 2022 23

View entire presentation